Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

Heber Siachoque; Milcíades Ibañez

Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

Resumen

Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p

Idioma original	Inglés estadounidense
Páginas (desde-hasta)	375-381
Número de páginas	7
Publicación	Colombia Medica
Estado	Publicada - oct. 1 2007

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Citar esto

@article{058c02e41c1044a6b31751002d399fee,

title = "Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia",

abstract = "Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p",

author = "Heber Siachoque and Milc{\'i}ades Iba{\~n}ez",

year = "2007",

month = oct,

day = "1",

language = "English (US)",

pages = "375--381",

journal = "Colombia Medica",

issn = "0120-8322",

publisher = "Universidad del Valle",

}

TY - JOUR

T1 - Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

AU - Siachoque, Heber

AU - Ibañez, Milcíades

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p

AB - Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p

M3 - Article

SN - 0120-8322

SP - 375

EP - 381

JO - Colombia Medica

JF - Colombia Medica

ER -

Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

Resumen

ODS de las Naciones Unidas

Huella

Citar esto